Dr. RR Baliga's 'Podkast for the Kurious Doc'

Dr. RR Baliga's 'Podkast for the Kurious Doc'

A landmark study in the New England Journal of Medicine shows that hypertension control is no longer just about prescribing medications—it’s about systems, teams, and sustained engagement. 🩺📊   In a cluster-randomized trial across underserved populations, a multifaceted, team-based strategy—combining protocol-driven care, health coaching, and home BP monitoring—achieved a significant additional reduction of −6.4 mm Hg in systolic BP (P<0.001) and improved adherence.   The message is clear: 👉 Evidence works—but only when implemented well 👉 Teams outperform...

Dr. RR Baliga's 'Podkast for the Kurious Doc'

Sex hormones shape cardiovascular risk in subtle yet powerful ways. From estrogen-driven changes in coagulation to formulation-specific differences in VTE risk, the nuance matters. Transdermal estradiol offers a safer path, while ethinyl estradiol reminds us that dose and route are destiny. The key is not avoidance—but precision: matching therapy to individual risk.   Three takeaways: • Formulation matters • First year matters • Patient factors matter   #Cardiology #Thrombosis #PrecisionMedicine #HormoneTherapy

Dr. RR Baliga's 'Podkast for the Kurious Doc'

  A landmark study on transcatheter tricuspid valve replacement (TTVR) offers compelling real-world evidence 🫀   ✅ 98.4% procedural success ✅ Near-complete TR elimination (97.7% at 30 days) ✅ Significant improvement in symptoms & quality of life ⚠️ Trade-off: ~16% new pacemaker rate in device-naïve patients   In an elderly, high-risk cohort, TTVR delivers what surgery often cannot—restoration without incision, relief without delay.   A meaningful step forward in structural heart disease—where the right heart finally takes center stage ✨

Dr. RR Baliga's 'Podkast for the Kurious Doc'

  A quiet shift, yet a profound one. 🧠   The OCEANIC-STROKE trial introduces asundexian, a Factor XIa inhibitor that lowers recurrent ischemic stroke risk (HR 0.74) without increasing major bleeding—a long-sought balance in antithrombotic therapy.   For decades, we traded efficacy for safety. Now, we may finally have both. ⚖️   The implications extend beyond stroke—to a broader rethinking of thrombosis itself: can we uncouple clot from bleed?   This study suggests we can.   #StrokePrevention #Cardiology #Neurology #ClinicalTrials #Anticoagulation...

Dr. RR Baliga's 'Podkast for the Kurious Doc'

  🧠 Brain metastases remain a clinical frontier—common, complex, and still lethal. In Science Signaling, Chafe et al. unpack the biology: Blood Brain Barrier traversal, metabolic rewiring, and immune evasion.   Key insight: metastasis is not just spread—it is adaptation.   From adenosine-driven immunosuppression to neuronal-like tumor states, new therapeutic doors are opening.   Precision oncology must now think beyond the primary tumor.   #BrainMetastases #Oncology #NeuroOncology #Immunotherapy #PrecisionMedicine

Dr. RR Baliga's 'Podkast for the Kurious Doc'

What if the roots of modern surgery were written over 2,000 years ago? 🩺📜   Meet —a pioneer whose Suśruta Saṃhitā laid the foundations of plastic surgery, cataract procedures, and structured medical training. From rhinoplasty to hands-on simulation using natural models, his approach was remarkably ahead of its time.   A reminder that innovation is often rediscovery—and that the future of medicine is deeply anchored in its past. 🌍✨   #HistoryOfMedicine #Ayurveda #Surgery #MedicalEducation #Innovation

Dr. RR Baliga's 'Podkast for the Kurious Doc'

  🧠💊 Stop. Test. Rethink.   A compelling new study in JAMA shows that ~26% of adults ≥60 years can safely discontinue levothyroxine, maintaining normal thyroid function—especially those on low doses (≤50 μg/day).   📉 No meaningful decline in quality of life 📊 Clear dose-response signal ⚠️ Raises concerns about lifelong overtreatment   The message is elegant: Not every prescription deserves permanence.   Time to reassess, deprescribe, and individualize—particularly in our older patients.   #Thyroid #Endocrinology #Deprescribing #Geriatrics...

Dr. RR Baliga's 'Podkast for the Kurious Doc'

A fascinating step forward in Nature—where immunology meets cardiology. 🧬❤️   This study shows that engineered dendritic cells can locally reprogram the immune response, reduce fibrosis, and improve cardiac function—without systemic immunosuppression.   The insight is simple, yet profound: 👉 Heart failure is not just hemodynamic—it is immunologic.   From FAP-targeted delivery to checkpoint-mediated tolerance (PD-L1, CTLA4-Ig, IL-10), this work opens the door to a new therapeutic paradigm—precision immunotherapy for heart failure. 🚀   The seeds of...

Dr. RR Baliga's 'Podkast for the Kurious Doc'

🧠⏳ Age. Biology. Truth.   A compelling Perspective in the New England Journal of Medicine challenges one of medicine’s quiet assumptions: that age equals risk.   Two patients may share a birth year—but not a biology. From epigenetic clocks to physiological reserve, the evidence is clear: chronologic age is an imperfect proxy for clinical decision-making    ⚠️ The consequence? Missed prevention in the young, withheld therapy in the old.   ✨ The opportunity? A shift toward biologically grounded, precision care—where treatment aligns not with years lived,...

Dr. RR Baliga's 'Podkast for the Kurious Doc'

Why do GLP-1 therapies transform some patients—and barely move the needle in others? 🧬💉   A recent Nature study (~28,000 participants) identifies GLP1R and GIPR variants linked to both weight loss efficacy and GI side effects.   📊 Signal: modest for weight loss, stronger for tolerability 🧠 Insight: genetics + clinical factors explain ~25% variability 🚀 Implication: early steps toward precision obesity therapeutics   The future may not be “one drug fits all,” but one genome, one strategy.